Bennett Selby Investments LP Raises Stake in Novo Nordisk A/S (NYSE:NVO)

Bennett Selby Investments LP lifted its position in Novo Nordisk A/S (NYSE:NVO) by 59.0% in the first quarter, HoldingsChannel.com reports. The firm owned 44,876 shares of the company’s stock after purchasing an additional 16,651 shares during the quarter. Novo Nordisk A/S comprises about 1.2% of Bennett Selby Investments LP’s investment portfolio, making the stock its 19th biggest holding. Bennett Selby Investments LP’s holdings in Novo Nordisk A/S were worth $3,116,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. GHP Investment Advisors Inc. raised its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. GHP Investment Advisors Inc. now owns 4,738 shares of the company’s stock valued at $408,000 after buying an additional 178 shares during the last quarter. Strategic Financial Concepts LLC lifted its holdings in shares of Novo Nordisk A/S by 8,384.4% in the fourth quarter. Strategic Financial Concepts LLC now owns 143,810 shares of the company’s stock worth $12,371,000 after buying an additional 142,115 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth $156,000. Finally, Platform Technology Partners grew its stake in Novo Nordisk A/S by 38.7% during the fourth quarter. Platform Technology Partners now owns 5,677 shares of the company’s stock valued at $488,000 after acquiring an additional 1,584 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $74.70 on Friday. The business’s 50 day moving average price is $65.87 and its 200-day moving average price is $80.54. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a market cap of $335.22 billion, a P/E ratio of 22.71, a P/E/G ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

NVO has been the topic of several research analyst reports. Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.